ClinicalTrials.gg
CompletedNCT06713746Updated Oct 1, 2026

Growth Differentiation Factor 15 in ICU Acquired Muscle Weakness

An observational study in Muscle Weakness, sponsored by Minia University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Minia University · Observational

How we know

Updated Oct 1, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
58
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Muscle Weakness with a site in Egypt — 4 open to participants now, 4 under way, none of them phase 3. Muscle Weakness · Egypt.

Started
2023
with 1 other
Observational
7 of 16
2 open now
Registered
6th of 16
by date
Lead sponsor
1 of 16
Minia University

Among the 16 studies in Muscle Weakness with a site in Egypt, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 6th registered.

Muscle Weakness

478 studies on the registry are indexed under Muscle Weakness; 72 are open to participants now.

Browse Muscle Weakness studies →

Open to participants now

4 of the 16 studies in Muscle Weakness with a site in Egypt are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 52 Muscle Weakness studies recruiting now, 25 (48%) set no upper age limit and 20 (38%) stop at 75 or younger; 5 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Muscle Weakness with a site in Egypt, or all of them as a file.
02

Study summary

Intensive care unit -acquired weakness (ICU- AW) is a common consequence linked to a worse outcome as evidenced by prolonged mechanical ventilation, longer ICU stays, greater mortality rates and a lower quality of life for survivors, so early detection and treatment of ICU-AW are critical. However, there is no "gold standard" currently available for assessing and diagnosing ICU-AW. It's crucial to develop diagnostic methods that enable for early detection and risk stratification in all critically ill patients, such as:

GDF-15 (growth differentiation factor-15) is thought to be a mediator of muscle atrophy because its level increases in the muscular atrophy As a result, measuring GDF-15 seems promise for diagnosing muscle atrophy.

Read the detailed description

After obtaining the approval of research ethical committee of faculty of medicine, Minia university, written informed consent will be obtained from all participants or their legal representatives prior to study inclusion, this prospective cross sectional non randomized observational study will be conducted in intensive care unit Minia university hospital, on conscious non-mechanically ventilated patients with expected ICU stay 7 days or more. Based on inclusion and exclusion criteria, patients who met eligibility criteria, the prognosis and outcome of patients developing ICU-AW will be observed.

Parameters will be assessed:

  1. Medical history, Age, gender, weight, BMI and APACHE II score ("Acute Physiology and Chronic Health Evaluation II") which is a severity-of-disease classification system one of several ICU scoring systems will be assessed in the day of admission.
  2. SOFA score ("Sequential Organ Failure Assessment ") which will be assessed every day.
  3. Routine lab investigations other than these in SOFA score as (Urea, Albumin, Hb, TLc, Pt, Ptt, RBG…..ect).
  4. Urea:creatinine ratio: Urea and creatinine will be measured daily as a part of SOFA score and urea to creat will be calculated.
  5. Plasma Growth differentiation 15 (GDF15) on 1, 4 and 7 days.
  6. Ultrasound measurement of rectus femoris cross-sectional area (RFcsa) on 1, 4, 7, 10 and then every 3days according to patients stay in ICU.
  7. Muscle Strength Assessment using the Medical Research Council (MRC) score on 1, 4 and 7 days where patients will be divided into an ICU-AW group and a non ICU-AW group according to their MRc-score on the 7th day.
  8. Length of hospital and ICU stay.
  9. Long term out come after 3 months survival, physical activity and return to work
03

Conditions studied

  • Muscle Weakness

Browse trials for

Keywords

  • GDF15 Muscle weakness ICU
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

patients older than 18, conscious non mechanically ventilated patients and those with expected ICU stay more than 7 days during the period from September 2023 to September 2024

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age more than 18 conscious patients patients with expected ICU stay more than 7 days

Exclusion criteria

Exclusion Criteria:

- unconscious patients spinal cord injury limb fracture or amputations history of cognitive dysfunction severe oedema end stage kidney disease

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
58 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • ICU patients

    muscle weakness

    Diagnostic Test: growth differentiation factor 15

Interventions

  • Diagnostic testgrowth differentiation factor 15

    rowth differentiation factor-15 (GDF-15) is a novel cytokine secreted by a variety of cells like macrophages, adipocytes, normally expressed in high amounts by placenta

    Also known as: urea to creatinine ratio

06

What researchers measure

Primary outcomes

  1. Incidence

    to investigate the incidence of intensive care unit acquired muscle weakness

    Time frame: 1 year

  2. Disease relations

    to examine if there is any correlation between GDF15 level or urea-creatinine ratio and ICU acquired muscle weakness

    Time frame: 1 year

Secondary outcomes

  1. Daily activity and mortality

    to investigate the influence of muscle weakness on daily activity and mortality of ICU acquired patients

    Time frame: 1 year

07

Study locations

1 site
  • Minia university
    Minya, Egypt
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2023 to primary completion in Oct 2024, 12 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Sep 2023 → Oct 2023, primary completion Sep 2024 → Oct 2024 and completion Sep 2024 → Nov 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2021
First posted
Dec 3, 2024
StartActual
Oct 1, 2023was Sep 2023
Primary completionActual
Oct 1, 2024was Sep 2024
CompletionActual
Nov 1, 2024was Sep 2024
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 10, 2023→Oct 1, 2023
Oct 1, 2026
Primary completion
Sep 10, 2024→Oct 1, 2024
Oct 1, 2026
Study completion
Sep 15, 2024→Nov 1, 2024
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Start date Sep 10, 2023→Oct 1, 2023
    Primary completion Sep 10, 2024→Oct 1, 2024
    Study completion Sep 15, 2024→Nov 1, 2024
    + 7 other changes: identifiers, verification date, oversight details, description, criteria formatting, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06713746
Lead sponsor
Minia University
Responsible party
Aya Hamdy Ahmed Nagy (Assistant lecturer of anesthesia and intensive care department, Minia University) — Principal investigator
First posted
Dec 3, 2024
Start date
Oct 1, 2023
Primary completion
Oct 1, 2024
Completion
Nov 1, 2024
Last update
Oct 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion